Versant Ventures is a healthcare investment firm founded in 1999 and based in San Francisco, California. It focuses on supporting exceptional entrepreneurs in building innovative companies across various sectors within healthcare, including biotechnology, life sciences, pharmaceuticals, and oncology. With $2.3 billion under management, the firm invests at all stages of company development, emphasizing the discovery and development of novel therapeutics. Versant’s team possesses extensive investment, operational, and scientific expertise, allowing for a hands-on approach to company building. Since its inception, more than 65 companies associated with Versant have successfully achieved acquisitions or initial public offerings, reflecting the firm’s commitment to fostering growth in the healthcare industry.
Tempest Therapeutics is a biotechnology company based in South San Francisco, California, that specializes in developing small molecule therapeutics for cancer treatment. Founded in 2011, the company focuses on innovative therapies that enhance anti-tumor immunity and directly target tumor cells. Its pipeline includes several clinical-stage candidates, notably TPST-1120, which blocks the PPAR-alpha pathway to stimulate immune response, and TPST-8844, designed to inhibit an enzyme that allows tumor cells to evade immune detection. Additionally, Tempest Therapeutics is working on compounds that target prostaglandins to counteract immune suppression. By pursuing these mechanisms, the company aims to create effective treatments that harness the body's own immune system to combat cancer.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. Its rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond.
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. Its rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
Matterhorn is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule. MR1 presents cancer-specific metabolites on the surface of cancer cells that are recognized and killed by T cells bearing a MR1-specific T cell receptor.
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. Its rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond.
Tempest Therapeutics is a biotechnology company based in South San Francisco, California, that specializes in developing small molecule therapeutics for cancer treatment. Founded in 2011, the company focuses on innovative therapies that enhance anti-tumor immunity and directly target tumor cells. Its pipeline includes several clinical-stage candidates, notably TPST-1120, which blocks the PPAR-alpha pathway to stimulate immune response, and TPST-8844, designed to inhibit an enzyme that allows tumor cells to evade immune detection. Additionally, Tempest Therapeutics is working on compounds that target prostaglandins to counteract immune suppression. By pursuing these mechanisms, the company aims to create effective treatments that harness the body's own immune system to combat cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.